Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Open-label, Randomized, Active-Controlled Study of Efficacy and Safety of AND017 in the Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis

NCT05265325 is registered in ClinicalTrials.gov with Kind Pharmaceuticals LLC as lead sponsor.

NCT NCT05265325
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05265325 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Open-label, Randomized, Active-Controlled Study of Efficacy and Safety of AND017 in the Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis
Lead sponsor
Kind Pharmaceuticals LLC
Phase
Phase 2
Overall status
Completed
Start date
May 3, 2023
Completion date
April 25, 2024
Enrollment
175 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

renal anemia